Microbot Medical Inc. 8-K

What Happened
On March 26, 2026, Microbot Medical Inc. filed a Form 8-K (Regulation FD disclosure) reporting a joint press release with Emory Healthcare announcing that Emory clinicians have successfully completed robotic peripheral endovascular procedures using Microbot’s LIBERTY® Endovascular Robotic System. Emory interventional radiologists demonstrated successful use of the LIBERTY System on benign prostatic hyperplasia (BPH) and liver cancer. The press release is furnished as Exhibit 99.1 to the 8-K.

Key Details

• Filing date: March 26, 2026 (Form 8-K, Regulation FD disclosure).
• Partner: Emory Healthcare (joint press release).
• Device: LIBERTY® Endovascular Robotic System.
• Reported procedures: robotic peripheral endovascular treatments for BPH and liver cancer; press release filed as Exhibit 99.1.

Why It Matters
This 8-K records a reported clinical milestone and public disclosure of Emory Healthcare’s use of Microbot’s LIBERTY system. The filing does not include financial results, guidance, or other quantitative business metrics—investors should view it as a company disclosure about clinical application rather than a financial update.